Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Surgery, Mayo Clinic, Rochester, MN, United States of America.
Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, United States of America.
Gynecol Oncol. 2023 Jul;174:11-20. doi: 10.1016/j.ygyno.2023.04.014. Epub 2023 May 2.
Alterations in DNA methylation are early events in endometrial cancer (EC) development and may have utility in EC detection via tampon-collected vaginal fluid.
For discovery, DNA from frozen EC, benign endometrium (BE), and benign cervicovaginal (BCV) tissues underwent reduced representation bisulfite sequencing (RRBS) to identify differentially methylated regions (DMRs). Candidate DMRs were selected based on receiver operating characteristic (ROC) discrimination, methylation level fold-change between cancers and controls, and absence of background CpG methylation. Methylated DNA marker (MDM) validation was performed using qMSP on DNA from independent EC and BE FFPE tissue sets. Women ≥45 years of age with abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB) or any age with biopsy-proven EC self-collected vaginal fluid using a tampon prior to clinically indicated endometrial sampling or hysterectomy. Vaginal fluid DNA was assayed by qMSP for EC-associated MDMs. Random forest modeling analysis was performed to generate predictive probability of underlying disease; results were 500-fold in-silico cross-validated.
Thirty-three candidate MDMs met performance criteria in tissue. For the tampon pilot, 100 EC cases were frequency matched by menopausal status and tampon collection date to 92 BE controls. A 28-MDM panel highly discriminated between EC and BE (96% (95%CI 89-99%) specificity; 76% (66-84%) sensitivity (AUC 0.88). In PBS/EDTA tampon buffer, the panel yielded 96% (95% CI 87-99%) specificity and 82% (70-91%) sensitivity (AUC 0.91).
Next generation methylome sequencing, stringent filtering criteria, and independent validation yielded excellent candidate MDMs for EC. EC-associated MDMs performed with promisingly high sensitivity and specificity in tampon-collected vaginal fluid; PBS-based tampon buffer with added EDTA improved sensitivity. Larger tampon-based EC MDM testing studies are warranted.
DNA 甲基化的改变是子宫内膜癌(EC)发展的早期事件,并且可能通过阴道拭子采集的阴道液在 EC 检测中具有实用性。
在发现阶段,来自冷冻的 EC、良性子宫内膜(BE)和良性宫颈阴道(BCV)组织的 DNA 进行了简化代表性亚硫酸氢盐测序(RRBS),以鉴定差异甲基化区域(DMR)。基于接收者操作特征(ROC)区分、癌症和对照之间的甲基化水平变化倍数以及不存在背景 CpG 甲基化,选择候选 DMR。使用独立的 EC 和 BE FFPE 组织集上的 qMSP 对甲基化 DNA 标记物(MDM)进行验证。对有异常子宫出血(AUB)或绝经后出血(PMB)的年龄≥45 岁的妇女,或任何年龄经活检证实的 EC 患者,使用阴道拭子自行采集阴道液,然后在临床需要的子宫内膜取样或子宫切除术前进行。通过 qMSP 对阴道液 DNA 进行 EC 相关 MDM 检测。进行随机森林建模分析以生成潜在疾病的预测概率;结果在 500 倍的内部交叉验证中得到验证。
33 个候选 MDM 在组织中符合性能标准。对于拭子试验,100 例 EC 病例按绝经状态和拭子采集日期与 92 例 BE 对照进行频数匹配。28 个 MDM 标志物面板高度区分了 EC 和 BE(96%(95%CI 89-99%)特异性;76%(66-84%)敏感性(AUC 0.88))。在 PBS/EDTA 阴道拭子缓冲液中,该面板的特异性为 96%(95%CI 87-99%),敏感性为 82%(70-91%)(AUC 0.91)。
下一代甲基组测序、严格的筛选标准和独立验证产生了用于 EC 的优秀候选 MDM。在阴道拭子采集的阴道液中,与 EC 相关的 MDM 表现出高灵敏度和特异性,PBS 为基础的拭子缓冲液中加入 EDTA 可提高敏感性。需要进一步开展基于阴道拭子的更大规模的 EC MDM 检测研究。